International Journal of Drug Delivery Technology
Volume 14, Issue 2

Effect of Magnesium Stearate and Fines on Delivery of Dry Powder for Inhalation using Sucrose as a Carrier

Ganesh Jadhav1*, Milind Wagh1, Nazma Inamdar2

1Maratha Vidya Prasarak Samaj’s College of Pharmacy, Nashik, Maharashtra, India.

2Government College of Pharmacy, Amravati, Maharashtra, India. 

Received: 15th March, 2023; Revised: 16th April, 2024; Accepted: 10th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Typically, lactose is utilised as carrier in Dry Powder Inhaler commercially. However, with the widening scope of DPI in therapeutic categories other than COPD and asthma, a need for the alternate carrier is arising. In this study, we used sucrose, a non-reducing sugar, as an alternate carrier. Effect of addition of fines and magnesium stearate was studied on powder flow properties and aerosolization performance. The air jet milling technique was used to generate sucrose fines. DSC and XRD studies showed no change in sucrose polymorph upon micronization. Levosalbutamol sulphate was used as a model drug, powder blends were prepared by low shear tumbling type blender. Powder formulations were studied for PSD, blend homogeneity, and flow properties. The percentage of particles smaller than 5 microns rose when fines were added as indicated by PSD data. SEM study revealed that the added fines get adsorbs on the coarse carrier, thus minimizing the adhesive interactions between drug and coarse carrier. In-vitro deposition was studied using low and high resistance devices on glass Twin Stage Impinger (TSI). Addition of fines and the magnesium stearate improves aerosolization performance showing higher Fine Particle Fraction (FPF) by almost 2 folds than the formulation containing coarse carrier alone.

Keywords: Dry powder for inhalation, Sucrose, Magnesium stearate, Particle size, Fines. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.35

How to cite this article: Jadhav G, Wagh M, Inamdar N. Effect of Magnesium Stearate and Fines on Delivery of Dry Powder for Inhalation using Sucrose as a Carrier. International Journal of Drug Delivery Technology. 2024;14(2):839-846.

REFERENCES

  1. Ye, , Y. Ma, and J. Zhu. 2022. The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?. Int.Pharm, 121457. doi: 10.1016/j.ijpharm.2022.121457.
  2. Besenhard, M. O., E. Faulhammer, S. Fathollahi, G. Reif, V. Calzolari, Biserni, A. Ferrari, S.M. Lawrence, M. Llusa, and J.G. Khinast. 2015. Accuracy of micro powder dosing via a vibratory sieve–chute system. Eur J Pharm Biopharm. 94: 264-doi: 10.1016/j.ejpb.2015.04.037.
  3. Hickey, A. J. 2003. Pharmaceutical Inhalation Aerosol Technology. 3rd ed. Boca Raton: CRC Press. https://doi. org/10.1201/9780203912898
  4. Hebbink, A., M. Jaspers, H.J. Peters, and B.H. Dickhoff. 2022. Recent developments in lactose blend formulations for carrier- based dry powder inhalation. Adv. Drug Deliv. Rev. 114527. doi: 10.1016/j.addr.2022.114527
  5. Kou, , L.W. Chan, H. Steckel, and P.W. Heng. 2012. Physico- chemical aspects of lactose for inhalation. Adv. Drug Deliv. Rev. 64(3), 220-232. doi: 10.1016/j.addr.2011.11.004.
  6. Lee, J., H.G. Lee, Y.B. Kwon, J.Y. Kim, Y.S. Rhee, J. Chon,and C.W. Park. 2018. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation. Eur. J. Pharm. Sci. 117: 279-289.doi: 10.1016/j.ejps.2018.03.004.
  7. Kaialy, W., and A. Nokhodchi. 2015. Dry powder inhalers: physicochemical and aerosolization properties of several size- fractions of a promising alterative carrier, freeze-dried Eur. J. Pharm. Sci. 68:56-67. doi: 10.1016/j.ejps.2014.12.005
  8. Della Bella, A., E. Salomi, F. Buttini, and R. Bettini. 2018. The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery. Expert Opin. Drug Deliv. 15(7):665-674. doi:10.1080/17425247.2017.1371132
  9. Benassi, , I.Perazzi, R. Bosi, C. Cottini, and R. Bettini. 2019. Quantifying the loading capacity of a carrier-based DPI formulation and its dependence on the blending process. Powder Technol. 356: 607-617. doi: 10.1016/j.powtec.2019.08.109.
  10. Pilcer, G., and Amighi, K. 2010. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1- 2):1-19. doi:10.1016/j.ijpharm.2010.03.017.
  11. Hariyadi, M., Hendradi, E., and Sharon, N. 2019. Development of carrageenan polymer for encapsulation of ciprofloxacin HCL: In vitro characterization. International Journal of Drug Delivery Technology, 9(1), 89-93. doi: 10.25258/ijddt.9.1.14
  12. Hariyadi MD, Hendradi E and Deliaz FM. 2023. Polymeric Fluoroquinolone Microparticles for Pulmonary Drug Delivery: A Review on Characteristics, Drug Release Profile, and Antibacterial Study. International Journal of Drug Delivery Technology;13(3):1037-1045. doi: 10.25258/ijddt.13.3.44
  13. Bukkawar A, A Jain and V Chatap. 2023. Development and Evaluation of Vasoactive Intestinal Peptide Freeze-Dried Injection. International Journal of Drug Delivery Technology. 13(2):597-604. doi: 10.25258/ijddt.13.2.21
  14. Rodge, P., and S. Shirolkar. 2023. Centrifugal Melt Spun Microfibrous Solid Dispersion of Diclofenac Sodium with Enhanced Solubility. International Journal of Pharmaceutical Quality Assurance. 14(1):165-170. doi: 10.25258/ijpqa.14.1.28
  15. Smyth, H.D., and M. Donovan. 2011. Formulations Containing Large-Size Carrier Particles for Dry Powder Inhalation US Patent 2011/0253140 A1, filed July 30, 2009, and issued October 20, 2011
  16. Tseti, 2021. A Pharmaceutical Dry Powder Composition for Inhalation Comprising a Thyroid Hormone. US Patent 2021/0077391 A1, filed April 10, 2019, and issuedMarch 18, 2021
  17. Shetty, , H. Park, D. Zemlyanov, S. Mangal, S. Bhujbal, and Q. T. Zhou. 2018. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. Int. J. Pharm, 544(1):222-234. doi: 10.1016/j.ijpharm.2018.04.034
  18. Babenko, M., J.M.R. Peron, W. Kaialy, G. Calabrese, R.G. Alany, and A. EIShaer. 2019. 1H NMR quantification of spray dried and spray freeze-dried saccharide carriers in dry powder inhaler formulations. Int. J. Pharm. 564:318-328.doi:10.1016/j. 2019.03.030.
  19. Weers, J. G., D. P. Miller. 2015. Formulation design of dry powders for inhalation. J. Pharm. Sci.104(10):3259-3288. doi: 1002/jps.24574.
  20. Rudén, J., G. Frenning, T. Bramer, K. Thalberg, J. An, and G. Alderborn. 2019. Linking carrier morphology to the powder mechanics of adhesive mixtures for dry powder inhalers via a blend-state model. Int. J. Pharm, 561:148-160. doi:10.1016/j. 2019.02.038.
  21. Islam, N., P. Stewart, I. Larson, and P. Hartley. 2004. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose- interactive mixtures? Res. 21, 492-499. doi: 10.1023/B:P HAM.0000019304.91412.18
  22. Elsayed, M. M., and A.O. Shalash. 2018. Modeling the performance of carrier-based dry powder inhalation formulations: Where are we, and how to get there?. J Control Release, 279, 251-261.doi:10.1016/j.jconrel.2018.03.020.
  23. Steckel, H., P. Markefka, R. Kammelar. 2004. Functionality testing of inhalation grade lactose. Eur J Pharm Biopharm. 57(3):495-505. doi: 10.1016/j.ejpb.2003.12.003.
  24. Steckel, , and N. Bolzen. 2004. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 270(1-2):297-306. doi: 10.1016/j.ijpharm.2003.10.039.
  25. Grasmeijer, , A.J. Lexmond, M. van den Noort, P. Hagedoorn, A.J. Hickey, H.W. Frijlink, and A. H. de Boer. 2014. New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation. PLOS one. 9(1):e87825.doi: 10.1371/journal.pone.0087825.
  26. Bungert, N., M. Kobler, and R. Scherließ. 2022. Proof-of- Concept for Adjusted Surface Energies and Modified Fines as a Novel Concept in Particle Engineering for DPI Formulations. Pharmaceutics, 14(5):951.doi: 10.3390/pharmaceutics14050951.
  27. Ratnaparakhi, M. et al. 2023. Formulation and Evaluation of Moxifloxacin Dry Powder Inhaler Combined with Mucolytic Agent for Pulmonary Diseases. International Journal of Drug Delivery Technology. 2023;13(3):818-824. doi: 10.25258/ 13.3.07
  28. Shur, , R. Price, D. Lewis, P.M. Young, G. Woollam, D. Singh, and S. Edge. 2016. From single excipients to dual excipient platforms in dry powder inhaler products. Int. J. Pharm. 514(2):374-383. doi: 10.1016/j.ijpharm.2016.05.057.
  29. Mehta, P. (2018). Imagine the superiority of dry powder inhalers from carrier engineering. J. Drug Deliv. 5635010. doi: 1155/2018/5635010.
  30. Narendra, N., and G.S. Jeyabalan, 2013. Method Development and validation of Levosalbutamol sulphate by Derivative Spectroscopy. J.D.Med. 5(1):84-89.
  31. Begat, , D. A. Morton, J. Shur, P. Kippax, J.N. Staniforth, and R. Price. 2009. The role of force control agents in high dose dry powder inhaler formulations. J Pharm Sci. 98(8):2770-2783. doi:10.1002/jps.21629.
  32. Jones, M. D., and R. Price, R. 2006. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm. Res. 23, 1665-1674. doi: 10.1007/s11095-006-9012-7.
  33. Lee, T., and G.D. Chang. 2009. Sucrose conformational polymorphism: a jigsaw puzzle with multiple routes to a unique Cryst Growth Des. 9(8):3551-3561. doi:10.1021/ cg900294d.
  34. Umerska, , N.A. Mugheirbi, A. Kasprzak, P. Saulnier, and L. Tajber. 2020. Carbohydrate-based Trojan microparticles as carriers for pulmonary delivery of lipid nanocapsules using dry powder inhalation. Powder Technol, 364, 507-521. doi:10.1016/j. powtec.2020.02.028.
  35. Chinachoti, P., and M.P. Steinberg. 1986. Crystallinity of sucrose by X‐ray diffraction as influenced by absorption versus desorption, waxy maize starch content, and water activity. J. Food Sci, 51(2), 456-459. doi:10.1111/j.1365-2621.1986.tb11154.x.
  36. Sanchis, , C. Corrigan, M.L. Levy, and J. L. Viejo. 2013. Inhaler devices–from theory to practice. Respir. Med. 107(4):495-502. doi: 10.1016/j.rmed.2012.12.007.
  37. Kaialy, W., and A. Nokhodchi. 2013. Engineered mannitol ternary additives improve dispersion of lactose–salbutamol sulphate dry powder AAPS J. 15, 728-743. doi: 10.1208/s12248- 013-9476-4.
  38. Steckel, , and B.W. Müller, B. W. 1997. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int. J. Pharm, 154(1):19-29. doi:10.1016/S0378-5173(97)00113-0
  39. Kinnunen, , G. Hebbink, H. Peters, J. Shur, and R Price, R. 2014. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks. AAPS PharmSciTech.15:1009-1020. doi: 10.1208/s12249-014-0108-9
  40. Zhou, , L. Qu, T. Gengenbach, I. Larson, P.J. Stewart, and D.A. Morton. 2013. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS Pharmscitech, 14, 38-44. doi: 10.1208/ s12249-012-9895-z